Prenetics Global Limited (NASDAQ:PRE – Free Report) – Stock analysts at Sidoti issued their Q1 2028 earnings estimates for Prenetics Global in a research report issued to clients and investors on Wednesday, July 15th. Sidoti analyst A. Hantman anticipates that the company will earn $0.28 per share for the quarter. The consensus estimate for Prenetics Global’s current full-year earnings is ($1.40) per share. Sidoti also issued estimates for Prenetics Global’s Q2 2028 earnings at $0.44 EPS and FY2028 earnings at $2.13 EPS.
Prenetics Global (NASDAQ:PRE – Get Free Report) last released its earnings results on Wednesday, June 10th. The company reported ($0.56) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.07). Prenetics Global had a negative return on equity of 20.33% and a negative net margin of 62.45%.The firm had revenue of $35.95 million for the quarter, compared to analyst estimates of $36.00 million.
Check Out Our Latest Research Report on PRE
Prenetics Global Stock Down 7.8%
Prenetics Global stock opened at $19.58 on Thursday. The business has a 50 day moving average price of $18.60 and a two-hundred day moving average price of $18.46. The stock has a market cap of $330.39 million, a price-to-earnings ratio of -4.28 and a beta of 0.26. Prenetics Global has a 12 month low of $7.18 and a 12 month high of $23.63.
Institutional Trading of Prenetics Global
A number of institutional investors and hedge funds have recently added to or reduced their stakes in PRE. Wells Fargo & Company MN acquired a new position in Prenetics Global in the fourth quarter worth about $47,000. State of Wyoming acquired a new stake in Prenetics Global during the first quarter valued at approximately $48,000. JPMorgan Chase & Co. acquired a new stake in Prenetics Global during the third quarter valued at approximately $65,000. Manatuck Hill Partners LLC bought a new stake in shares of Prenetics Global in the 4th quarter valued at approximately $170,000. Finally, T3 Companies LLC bought a new stake in shares of Prenetics Global in the 4th quarter valued at approximately $170,000. Institutional investors own 25.01% of the company’s stock.
About Prenetics Global
Prenetics Global (NASDAQ: PRE) is a molecular diagnostics and genetic testing company that delivers a broad range of laboratory and at-home testing solutions. The company’s core offerings include next-generation sequencing (NGS) panels for hereditary health risks, pharmacogenomic reports to guide medication choices, and comprehensive consumer DNA testing services. In addition to genetic insights, Prenetics provides infectious disease diagnostics—most notably real-time PCR testing for pathogens such as SARS-CoV-2—through an integrated platform that combines sample collection, laboratory processing and digital reporting.
Serving both business-to-consumer and business-to-business markets, Prenetics operates a network of laboratories and service centers across Asia Pacific, Europe, the Middle East and North America.
Featured Stories
- Five stocks we like better than Prenetics Global
- Why Johnson & Johnson’s Earnings Dip Looks Like a Buying Opportunity
- CPI Comes In Cool: Why It Could Revive These 3 Rate-Sensitive Stocks
- Why ASML’s AI Monopoly Is Still Getting Stronger
- Apple’s AI Toll Booth Thesis Faces Its Biggest Test Yet Before Earnings
Receive News & Ratings for Prenetics Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prenetics Global and related companies with MarketBeat.com's FREE daily email newsletter.
